Joseph D Khoury1. 1. Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, MS-072, Houston, TX, 77030, USA. jkhoury@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS: TCF4 is a master regulator that drives donwstream transcriptional programs in BPDCN. In turn, TCF4 activity is dependent on the bromodomain and extra-terminal domain (BET) protein BRD4 whose inhibition provides a promising therapeutic vulnerability. Notably, TCF4 expression is a highly sensitive marker for BPDCN and augments diagnostic specificity alongside CD4, CD56, CD123, and TCL1. The gene expression profile of BPDCN is characterized by aberrant NF-kappaB pathway activation, while its genomic landscape is dominated by structural chromosomal alterations involving ETV6, MYC, and NR3C1, as well as mutations in epigenetic regulators particularly TET2. Advances in elucidating the biological characteristics of BPDCN are resulting in a more refined diagnostic approach and are opening novel therapeutic avenues for patients with this disease.
PURPOSE OF REVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in BPDCN. In turn, TCF4 activity is dependent on the bromodomain and extra-terminal domain (BET) protein BRD4 whose inhibition provides a promising therapeutic vulnerability. Notably, TCF4 expression is a highly sensitive marker for BPDCN and augments diagnostic specificity alongside CD4, CD56, CD123, and TCL1. The gene expression profile of BPDCN is characterized by aberrant NF-kappaB pathway activation, while its genomic landscape is dominated by structural chromosomal alterations involving ETV6, MYC, and NR3C1, as well as mutations in epigenetic regulators particularly TET2. Advances in elucidating the biological characteristics of BPDCN are resulting in a more refined diagnostic approach and are opening novel therapeutic avenues for patients with this disease.
Authors: L Chaperot; N Bendriss; O Manches; R Gressin; M Maynadie; F Trimoreau; H Orfeuvre; B Corront; J Feuillard; J J Sotto; J C Bensa; F Brière; J Plumas; M C Jacob Journal: Blood Date: 2001-05-15 Impact factor: 22.113
Authors: M R Sapienza; F Fuligni; C Agostinelli; C Tripodo; S Righi; M A Laginestra; A Pileri; M Mancini; M Rossi; F Ricci; A Gazzola; F Melle; C Mannu; F Ulbar; M Arpinati; M Paulli; T Maeda; D Gibellini; L Pagano; N Pimpinelli; M Santucci; L Cerroni; C M Croce; F Facchetti; P P Piccaluga; S A Pileri Journal: Leukemia Date: 2014-02-07 Impact factor: 11.528
Authors: Fanny Angelot-Delettre; Anne Roggy; Arthur E Frankel; Baptiste Lamarthee; Estelle Seilles; Sabeha Biichle; Bernard Royer; Eric Deconinck; Eric K Rowinsky; Christopher Brooks; Valerie Bardet; Blandine Benet; Hind Bennani; Zehaira Benseddik; Agathe Debliquis; Daniel Lusina; Mikael Roussel; Françoise Solly; Michel Ticchioni; Philippe Saas; Francine Garnache-Ottou Journal: Haematologica Date: 2014-11-07 Impact factor: 9.941
Authors: Babacar Cisse; Michele L Caton; Manfred Lehner; Takahiro Maeda; Stefanie Scheu; Richard Locksley; Dan Holmberg; Christiane Zweier; Nicolette S den Hollander; Sarina G Kant; Wolfgang Holter; Anita Rauch; Yuan Zhuang; Boris Reizis Journal: Cell Date: 2008-10-03 Impact factor: 41.582
Authors: Khaled Alayed; Keyur P Patel; Sergej Konoplev; Rajesh R Singh; Mark J Routbort; Neelima Reddy; Naveen Pemmaraju; Liping Zhang; Abdulaziz Al Shaikh; Tariq N Aladily; Nitin Jain; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury Journal: Am J Hematol Date: 2013-09-30 Impact factor: 10.047
Authors: Katsuhiro Togami; Timothy Pastika; Jason Stephansky; Mahmoud Ghandi; Amanda L Christie; Kristen L Jones; Carl A Johnson; Ross W Lindsay; Christopher L Brooks; Anthony Letai; Jeffrey W Craig; Olga Pozdnyakova; David M Weinstock; Joan Montero; Jon C Aster; Cory M Johannessen; Andrew A Lane Journal: J Clin Invest Date: 2019-11-01 Impact factor: 14.808
Authors: C Cameron Yin; Naveen Pemmaraju; M James You; Shaoying Li; Jie Xu; Wei Wang; Zhenya Tang; Omar Alswailmi; Kapil N Bhalla; Muzaffar H Qazilbash; Marina Konopleva; Joseph D Khoury Journal: Cancers (Basel) Date: 2021-11-23 Impact factor: 6.639
Authors: Wei Wang; Joseph D Khoury; Roberto N Miranda; Jeffrey L Jorgensen; Jie Xu; Sanam Loghavi; Shaoying Li; Naveen Pemmaraju; Than Nguyen; Jeffrey L Medeiros; Sa A Wang Journal: Haematologica Date: 2021-04-01 Impact factor: 9.941